Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer
Status:
Completed
Trial end date:
2018-03-15
Target enrollment:
Participant gender:
Summary
Patients with pretreated, Her2-negative, advanced breast cancer will receive chemotherapy
with capecitabine and bendamustine for a maximum of eight cycles and afterwards capecitabine
alone until disease progression or unacceptable toxic effects. Safety assessments will be
conducted in 3-weekly intervals, efficacy assessments (CT or MRI) will be conducted every 9
weeks.
Aim of this study is to determine whether treatment with capecitabine in combination with
bendamustine is efficacious and safe.